li001

Organometallic complexes—cancer-fighting compounds built around metal-carbon bonds—are emerging as a more selective alternative to traditional platinum drugs like cisplatin. While platinum treatments remain effective, they often damage healthy cells and quickly lead to resistance. New metal-based designs aim to target cancer more precisely and avoid these limitations. Cyclometalated complexes are especially promising because their chemistry […]

NaPi2b, a sodium-dependent phosphate transporter, is emerging as a promising target for platinum-resistant ovarian cancer, a setting with few effective treatments. Highly expressed in high-grade serous ovarian, fallopian tube, and peritoneal cancers—but low in normal tissue—NaPi2b is ideal for selective delivery via antibody-drug conjugates (ADCs). Earlier NaPi2b-targeted ADCs, like lifastuzumab vedotin and upifitamab rilsodotin, showed

A new study suggests that GLP-1 receptor agonists—including Ozempic, Wegovy, and Mounjaro—may improve survival in patients with colon cancer. These drugs, commonly used for type 2 diabetes and weight loss, were linked to a five-year mortality rate of 15.5%, compared with 37.1% in patients not taking them, meaning users were less than half as likely

DB-1305/BNT325 is an investigational antibody-drug conjugate (ADC) designed to target TROP-2, a protein commonly found on triple-negative breast cancer (TNBC) cells. Once attached, it delivers a topoisomerase-1 inhibitor to help kill the cancer. Each antibody carries about four drug molecules. This treatment is being tested in a Phase 1/2 study in patients with metastatic TNBC